Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Your research
Country: Germany,Spain,Australia,United Kingdom,Belgium,Canada,Switzerland,United States,Korea, Republic of
nct
Update Il y a 5 ans
BUILD 3: Bosentan Use in Interstitial Lung Disease
BUILD 3 is a prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, event-driven, group sequential, phase III superiority study. The primary objective is to demonstrate that bosentan delays disease worsening or death in patients with Idiopathic Pulmonary Fibrosis.
Country
Australia
,
Austria
,
Belgium
,
Canada
,
Croatia
,
Czech Republic
,
France
,
Germany
,
Ireland
,
Israel
,
Italy
,
Japan
,
Korea, Republic of
,
Netherlands
,
Serbia
,
Spain
,
Switzerland
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 (NCT00391443) will asses the long term safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis (IPF).
Country
Australia
,
Belgium
,
Canada
,
Czech Republic
,
France
,
Germany
,
Ireland
,
Israel
,
Italy
,
Japan
,
Korea, Republic of
,
Spain
,
Switzerland
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib
Retrospective correlation of clinical outcomes data with mutational status in GIST subjects treated with sunitinib.
Country
Australia
,
Belgium
,
Canada
,
Denmark
,
Finland
,
France
,
Germany
,
India
,
Korea, Republic of
,
Netherlands
,
Poland
,
Slovakia
,
Spain
,
Switzerland
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
1